Deric L. Wheeler

6.2k citations

89 papers · 4.8k indexed · 1 hit paper · h-index 37

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
Cancer Research top 2%

Papers in

Oncology 56
- HER2/EGFR in Cancer Research 28
- Colorectal Cancer Treatments and Studies 10
- Pancreatic and Hepatic Oncology Research 6
- Cancer Immunotherapy and Biomarkers 5
Pulmonary and Respiratory Medicine 30
- Lung Cancer Treatments and Mutations 30

Co-authors: Mari Iida Emily Dunn Paul M. Harari Toni M. Brand Tim J. Kruser Eric A. Armstrong Chunrong Li Ajit Kumar Verma
Journals: Molecular Cancer Therapeutics (9 papers)Cancer Research (6 papers)Oncogene (5 papers)Clinical Cancer Research (4 papers)Cancer Biology & Therapy (4 papers)
Partner nations: United States Netherlands Germany

In The Last Decade

Deric L. Wheeler

84 papers receiving 4.7k citations

Hit Papers

align trajectories log scale

Understanding resistance to EGFR inhibitors—impact on future treatment strategies 2010 · 540 citations

Peers

Countries citing papers authored by Deric L. Wheeler

Since Specialization

Citations

This map shows the geographic impact of Deric L. Wheeler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deric L. Wheeler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deric L. Wheeler more than expected).

Fields of papers citing papers by Deric L. Wheeler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deric L. Wheeler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deric L. Wheeler. The network helps show where Deric L. Wheeler may publish in the future.

Co-authors

The 25 scholars most cited alongside Deric L. Wheeler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Deric L. Wheeler Line = papers co-authored together Deric L. Wheeler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response Advanced Healthcare Materials ·DaWon Kim, Jin Woong Lee, Piper A. Rawding, Mari Iida, Carter Kim, Kourtney L. Kostecki, Michael J. Poellmann, Bridget E. Crossman, A. Liu, Young Soo Kim, Deric L. Wheeler, Seungpyo Hong	2025	2
2	Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models Seminars in Radiation Oncology ·Liliana Berube, Kwangok P. Nickel, Mari Iida, Sravani Ramisetty, Prakash Kulkarni, Ravi Salgia, Deric L. Wheeler, Randall J. Kimple	2023	0
3	Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer Head & Neck ·Kourtney L. Kostecki, Mari Iida, Anne L. Wiley, Stanley Kimani, Bridget Mehall, Kaitlin Tetreault, Roxana Alexandridis, Menggang Yu, Seungpyo Hong, Ravi Salgia, Justine Y. Bruce, Raymond B. Birge, Paul M. Harari, Deric L. Wheeler	2023	7
4	AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer BMC Cancer ·Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin A. Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia, Deric L. Wheeler	2022	13
5	AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer Clinical Cancer Research ·Nellie K. McDaniel, Mari Iida, Kwangok P. Nickel, Colin A. Longhurst, Samantha R. Fischbach, Tamara S. Rodems, Carlene A. Kranjac, Amber Y. Bo, Qianyun Luo, Meghan M. Gallagher, Noah B. Welke, Kaitlyn R. Mitchell, Alison E. Schulz, Jaimee C. Eckers, Rong Hu, Ravi Salgia, Seungpyo Hong, Justine Y. Bruce, Randall J. Kimple, Deric L. Wheeler	2020	30
6	An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy Nano Letters ·Jiyoon Bu, Ashita Nair, Mari Iida, Woo‐jin Jeong, Michael J. Poellmann, Kara Mudd, Luke J. Kubiatowicz, Elizabeth W. Liu, Deric L. Wheeler, Seungpyo Hong	2020	91
7	Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers Cancers ·Aadhya Tiwari, Mari Iida, Corinna Kosnopfel, Mahyar Abbariki, Apostolos Menegakis, Birgit Fehrenbacher, Julia Maier, Martin Schaller, Sara Y. Brucker, Deric L. Wheeler, Paul M. Harari, Ulrich Rothbauer, Birgit Schittek, Daniel Zips, Mahmoud Toulany	2020	17
8	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas iScience ·Saumya Srivastava, Ka Ming Pang, Mari Iida, Michael S. Nelson, Jiayi Liu, Arin Nam, Jiale Wang, Isa Mambetsariev, Raju Pillai, Atish Mohanty, Nellie K. McDaniel, Amita Behal, Prakash Kulkarni, Deric L. Wheeler, Ravi Salgia	2020	10
9	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents Molecular Cancer Therapeutics ·Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hülse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham, Deric L. Wheeler	2018	41
10	Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma Cell Death and Disease ·Nathan Redlich, Anthony M. Robinson, Kwangok P. Nickel, Andrew P. Stein, Deric L. Wheeler, Douglas R. Adkins, Ravindra Uppaluri, Randall J. Kimple, Brian A. Van Tine, Loren S. Michel	2018	22
11	Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC Molecular Cancer Therapeutics ·Adam D. Swick, Prashanth J. Prabakaran, Margot C. Miller, Amal M. Javaid, Michael M. Fisher, Emmanuel Sampene, Irene M. Ong, Rong Hu, Mari Iida, Kwangok P. Nickel, Justine Y. Bruce, Deric L. Wheeler, Randall J. Kimple	2017	28
12	Adaptive responses to antibody based therapy Seminars in Cell and Developmental Biology ·Tamara S. Rodems, Mari Iida, Toni M. Brand, Hannah E. Pearson, Rachel A. Orbuch, Bailey G. Flanigan, Deric L. Wheeler	2016	5
13	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma Clinical Cancer Research ·Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, John P. Coan, Hannah E. Pearson, Harsh Bahrar, Tyler L. Fowler, Bryan P. Bednarz, Sandeep Saha, David T. Yang, Parkash S. Gill, Mark W. Lingen, Vassiliki Saloura, Victoria Villaflor, Ravi Salgia, Randall J. Kimple, Deric L. Wheeler	2015	89
14	AXL Mediates Resistance to Cetuximab Therapy Cancer Research ·Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, Neha Luthar, Mahmoud Toulany, Parkash S. Gill, Ravi Salgia, Randall J. Kimple, Deric L. Wheeler	2014	150
15	Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Toni M. Brand, Mari Iida, Emily Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David T. Yang, Kari B. Wisinski, Ravi Salgia, Deric L. Wheeler	2014	40
16	p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation Cancer Research ·Shyhmin Huang, Sergi Benavente, Eric A. Armstrong, Chunrong Li, Deric L. Wheeler, Paul M. Harari	2011	95
17	Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab Cancer Biology & Therapy ·Toni M. Brand, Emily Dunn, Mari Iida, Rebecca A. Myers, Kellie T. Kostopoulos, Chunrong Li, Chimera R. Peet, Deric L. Wheeler	2011	12
18	Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors Clinical Cancer Research ·Tim J. Kruser, Deric L. Wheeler, Eric A. Armstrong, Mari Iida, Kevin R. Kozak, Albert J. van der Kogel, Johan Bussink, Angela Coxon, Anthony Polverino, Paul M. Harari	2010	13
19	Mechanisms of resistance to HER family targeting antibodies Experimental Cell Research ·Tim J. Kruser, Deric L. Wheeler	2010	119
20	Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells Clinical Cancer Research ·Sergi Benavente, Shyhmin Huang, Eric A. Armstrong, Alexander Chi, Kun-Tai Hsu, Deric L. Wheeler, Paul M. Harari	2009	73

About Deric L. Wheeler

Deric L. Wheeler is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Cell Biology, having authored 89 papers that have together received 4.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (30 papers), HER2/EGFR in Cancer Research (28 papers), Phagocytosis and Immune Regulation (11 papers), Colorectal Cancer Treatments and Studies (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Oncology (2.5k citations), Cancer Research (751 citations), Otorhinolaryngology (195 citations), Pulmonary and Respiratory Medicine (1.3k citations) and Molecular Biology (2.5k citations). Deric L. Wheeler has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include Mari Iida, Emily Dunn, Paul M. Harari, Toni M. Brand, Tim J. Kruser, Eric A. Armstrong, Chunrong Li, Ajit Kumar Verma, Sergi Benavente and Neha Luthar. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Oncogene, Clinical Cancer Research and Cancer Biology & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact